These blue-chip stocks pay safe, generous dividends and form the foundation of a sturdy retirement portfolio.
Stocks moved higher, boosted by a series of earnings reports from the likes of Microsoft, Morgan Stanley and United Continental.
Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.
This health and drug giant is the best in its class. Here is why investors need to load up on J&J stock, which won't disappoint over the long run.
The company reported flat but in line earnings of $1.06 per share.
Better-than-expected earnings from Johnson & Johnson pushed the Dow Jones Industrial Average to close out the day with another record.
The pharmaceutical giant hits record high on better-than-expected second quarter earnings.
Johnson & Johnson's earnings reveal just how impressive growth is at the big pharma company, according to Jim Cramer.
The St. Louis-based target claims Bayer's revised $63.5 billion bid remains 'financially inadequate."
Abbott Labs -- with its 2.5% dividend yield and market underperformance -- will look safer when the market begins to rotate out of hotter stocks.
Can medical technology stocks continue their momentum higher in the second half of the year? Investors say yes, but technical analysis says not necessarily.
Pharmaceuticals sales once again drive growth in the health care group's second quarter.
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
BMO Capital Markets downgrades the pharmaceutical giant ahead of Q2 earnings as pricing pressure mounts and other potential headwinds begin to emerge.
With an average bang for your buck of 4.7% and growing payouts, these are all perfect for retirement portfolios.